JP2012525323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525323A5 JP2012525323A5 JP2011545129A JP2011545129A JP2012525323A5 JP 2012525323 A5 JP2012525323 A5 JP 2012525323A5 JP 2011545129 A JP2011545129 A JP 2011545129A JP 2011545129 A JP2011545129 A JP 2011545129A JP 2012525323 A5 JP2012525323 A5 JP 2012525323A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- solid preparation
- biphenyl
- ethoxy
- benzimidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims 12
- 239000011780 sodium chloride Substances 0.000 claims 12
- 239000007787 solid Substances 0.000 claims 11
- -1 1- (cyclohexyloxycarbonyloxy) ethyl Chemical group 0.000 claims 4
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 4
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 229960000528 amlodipine Drugs 0.000 claims 4
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000000480 calcium channel blocker Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- VVQNAFBGAWCMLU-UHFFFAOYSA-M 1H-benzimidazole-4-carboxylate Chemical compound [O-]C(=O)C1=CC=CC2=C1NC=N2 VVQNAFBGAWCMLU-UHFFFAOYSA-M 0.000 claims 1
- VVQNAFBGAWCMLU-UHFFFAOYSA-N 1H-benzimidazole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1N=CN2 VVQNAFBGAWCMLU-UHFFFAOYSA-N 0.000 claims 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 claims 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N 3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 claims 1
- 229950004646 Azelnidipine Drugs 0.000 claims 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical group CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 claims 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N Benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229950003102 Efonidipine Drugs 0.000 claims 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N Efonidipine Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 Erythritol Drugs 0.000 claims 1
- 229960003580 Felodipine Drugs 0.000 claims 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 claims 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N Manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 claims 1
- 229960001783 Nicardipine Drugs 0.000 claims 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 1
- 229960001597 Nifedipine Drugs 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 229960000227 Nisoldipine Drugs 0.000 claims 1
- 229960005425 Nitrendipine Drugs 0.000 claims 1
- PVHUJELLJLJGLN-UHFFFAOYSA-N Nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229960004916 benidipine Drugs 0.000 claims 1
- HTQMVQVXFRQIKW-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HTQMVQVXFRQIKW-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229960003020 cilnidipine Drugs 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 229960003963 manidipine Drugs 0.000 claims 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 1
- 229960005366 nilvadipine Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N Hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 2
- 229960003739 Methyclothiazide Drugs 0.000 description 2
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N Spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 229960003313 hydroflumethiazide Drugs 0.000 description 2
- 229950006804 methylclothiazide Drugs 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 0 *C1C(c2ccc(C[n]3c(O*)nc4c3c(*)ccc4)cc2)=CCCC1 Chemical compound *C1C(c2ccc(C[n]3c(O*)nc4c3c(*)ccc4)cc2)=CCCC1 0.000 description 1
- JCCBZCMSYUSCFM-UHFFFAOYSA-N 2-chlorobenzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1Cl JCCBZCMSYUSCFM-UHFFFAOYSA-N 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N 6-chloro-3-ethyl-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N Acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Arlix Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
- IIOPLILENRZKRV-UHFFFAOYSA-N Azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
- 229960004988 Azosemide Drugs 0.000 description 1
- BWSSMIJUDVUASQ-UHFFFAOYSA-N Benzylhydrochlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 BWSSMIJUDVUASQ-UHFFFAOYSA-N 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N Bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N Chlortalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N Cyclopenthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N Etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960002541 Ethacrynic Acid Drugs 0.000 description 1
- 229960003883 Furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N Furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 229960002479 Isosorbide Drugs 0.000 description 1
- SMNOERSLNYGGOU-UHFFFAOYSA-N Mefruside Chemical compound C=1C=C(Cl)C(S(N)(=O)=O)=CC=1S(=O)(=O)N(C)CC1(C)CCCO1 SMNOERSLNYGGOU-UHFFFAOYSA-N 0.000 description 1
- 229960001288 Triamterene Drugs 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triurene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 229940053550 agents used for ADHD and nootropics psychostimulants Xanthine derivatives Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 230000001864 anti-aldosterone Effects 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 229940006133 antiglaucoma drugs and miotics Carbonic anhydrase inhibitors Drugs 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 229950007003 benzylhydrochlorothiazide Drugs 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- GDDSFMMICZTVCA-UHFFFAOYSA-L calcium;2-carboxyphenolate;3,7-dimethylpurine-2,6-dione Chemical compound [Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.CN1C(=O)NC(=O)C2=C1N=CN2C GDDSFMMICZTVCA-UHFFFAOYSA-L 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic Effects 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229940083747 low-ceiling diuretics Xanthine derivatives Drugs 0.000 description 1
- 229960004678 mefruside Drugs 0.000 description 1
- 229960001085 piretanide Drugs 0.000 description 1
- WSRBRQQGWDWSON-UHFFFAOYSA-M sodium;3,7-dimethylpurine-2,6-dione;2-hydroxybenzoate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O.CN1C(=O)NC(=O)C2=C1N=CN2C WSRBRQQGWDWSON-UHFFFAOYSA-M 0.000 description 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011545129A JP5666471B2 (ja) | 2009-04-30 | 2010-04-28 | 固形製剤 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009111381 | 2009-04-30 | ||
JP2009111381 | 2009-04-30 | ||
JP2010068625 | 2010-03-24 | ||
JP2010068625 | 2010-03-24 | ||
JP2011545129A JP5666471B2 (ja) | 2009-04-30 | 2010-04-28 | 固形製剤 |
PCT/JP2010/057923 WO2010126168A2 (en) | 2009-04-30 | 2010-04-28 | Solid preparation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012525323A JP2012525323A (ja) | 2012-10-22 |
JP2012525323A5 true JP2012525323A5 (xx) | 2013-06-06 |
JP5666471B2 JP5666471B2 (ja) | 2015-02-12 |
Family
ID=43032637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011545129A Active JP5666471B2 (ja) | 2009-04-30 | 2010-04-28 | 固形製剤 |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP2424501A2 (xx) |
JP (1) | JP5666471B2 (xx) |
KR (1) | KR101797776B1 (xx) |
CN (1) | CN102481248B (xx) |
AU (1) | AU2010242308A1 (xx) |
BR (1) | BRPI1014388A2 (xx) |
CA (1) | CA2760073A1 (xx) |
CL (1) | CL2011002662A1 (xx) |
CO (1) | CO6470841A2 (xx) |
CR (1) | CR20110581A (xx) |
DO (1) | DOP2011000329A (xx) |
EA (1) | EA201171329A1 (xx) |
EC (1) | ECSP11011494A (xx) |
GE (1) | GEP20135940B (xx) |
IL (1) | IL215962A0 (xx) |
MA (1) | MA33280B1 (xx) |
MX (1) | MX2011011011A (xx) |
MY (1) | MY158158A (xx) |
NZ (1) | NZ596395A (xx) |
PE (1) | PE20120315A1 (xx) |
SG (1) | SG175794A1 (xx) |
TW (1) | TWI438201B (xx) |
WO (1) | WO2010126168A2 (xx) |
ZA (1) | ZA201108375B (xx) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL236001B1 (pl) | 2012-12-21 | 2020-11-30 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję |
KR101535586B1 (ko) * | 2014-08-01 | 2015-07-09 | 에스케이케미칼주식회사 | 무정형 또는 열역학적 준 안정형 리바록사반을 포함하는 약학 제제 |
KR101806004B1 (ko) * | 2015-01-30 | 2017-12-08 | 씨제이헬스케어 주식회사 | 칸데사르탄 및 암로디핀을 포함하는 약제학적 조성물 |
CN106668016B (zh) * | 2015-11-11 | 2020-06-23 | 江苏先声药业有限公司 | 阿齐沙坦和苯磺酸氨氯地平组合物的固体制剂及其制备方法 |
JP2017210435A (ja) * | 2016-05-25 | 2017-11-30 | ダイト株式会社 | イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法 |
JP2019001782A (ja) * | 2017-06-14 | 2019-01-10 | 東和薬品株式会社 | 二層錠 |
JP7101464B2 (ja) * | 2017-09-28 | 2022-07-15 | エルメッド株式会社 | アジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤の品質向上方法、並びにアジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤及びその製造方法 |
CN108210472A (zh) * | 2017-12-15 | 2018-06-29 | 蚌埠丰原医药科技发展有限公司 | 一种西尼地平固体分散体片剂及其制备方法 |
CN108685925B (zh) * | 2018-05-15 | 2019-12-06 | 徐州医科大学 | 一种化合物AB-38b在制备治疗糖尿病肾病药物方面的应用 |
JP2020075869A (ja) * | 2018-11-05 | 2020-05-21 | 日本ケミファ株式会社 | カルシウム拮抗剤及びアンジオテンシンii受容体拮抗剤を有効成分として含有する錠剤 |
JP7206872B2 (ja) * | 2018-12-07 | 2023-01-18 | ニプロ株式会社 | アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法 |
JP2020090471A (ja) * | 2018-12-07 | 2020-06-11 | ニプロ株式会社 | アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法 |
JP7441105B2 (ja) | 2020-03-31 | 2024-02-29 | 日本ジェネリック株式会社 | アジルサルタン及びアムロジピンベシル酸塩を含有するフィルムコーティング錠 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2814513B2 (ja) * | 1988-02-03 | 1998-10-22 | 吉富製薬株式会社 | 溶出性の改良された製剤組成物 |
JP3057471B2 (ja) * | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | アンジオテンシンii介在性諸疾患の予防または治療剤 |
CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
CA2416384A1 (en) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
EP1369130A1 (en) * | 2001-03-16 | 2003-12-10 | Takeda Chemical Industries, Ltd. | Process for producing sustained release preparation |
EP1452176A4 (en) * | 2001-12-03 | 2009-01-21 | Takeda Pharmaceutical | MEANS FOR IMPROVING INSULIN RESISTANCE |
AU2003235395A1 (en) * | 2002-05-22 | 2003-12-02 | Shionogi And Co., Ltd. | Pharmaceutical preparation improved in dissolving property of drug slightly soluble in water |
WO2004048363A1 (ja) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | イミダゾール誘導体、その製造法および用途 |
US7534887B2 (en) | 2003-09-30 | 2009-05-19 | Takeda Pharmaceutical Company Limited | Thiazoline derivative and use of the same |
CA2550012A1 (en) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same and use |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
JP2006321726A (ja) * | 2005-05-17 | 2006-11-30 | Sysmex Corp | 錠剤の溶出性調整方法 |
JP5148296B2 (ja) * | 2005-06-27 | 2013-02-20 | 第一三共株式会社 | アンジオテンシンii受容体拮抗剤及びカルシウム拮抗剤含有医薬組成物 |
JP5063370B2 (ja) * | 2005-06-27 | 2012-10-31 | 第一三共株式会社 | 湿式造粒製薬の調製方法 |
DE102005031577A1 (de) * | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten |
MY149356A (en) * | 2007-03-29 | 2013-08-30 | Daiichi Sankyo Co Ltd | Pharmaceutical composition |
UY32126A (es) * | 2008-09-25 | 2010-04-30 | Takeda Pharmaceutical | Composición farmacéutica sólida |
-
2010
- 2010-04-28 PE PE2011001882A patent/PE20120315A1/es not_active Application Discontinuation
- 2010-04-28 BR BRPI1014388A patent/BRPI1014388A2/pt not_active IP Right Cessation
- 2010-04-28 MY MYPI2011005206A patent/MY158158A/en unknown
- 2010-04-28 GE GEAP201012480A patent/GEP20135940B/en unknown
- 2010-04-28 JP JP2011545129A patent/JP5666471B2/ja active Active
- 2010-04-28 SG SG2011078391A patent/SG175794A1/en unknown
- 2010-04-28 KR KR1020117027421A patent/KR101797776B1/ko active IP Right Grant
- 2010-04-28 TW TW099113442A patent/TWI438201B/zh active
- 2010-04-28 EP EP10719654A patent/EP2424501A2/en not_active Withdrawn
- 2010-04-28 AU AU2010242308A patent/AU2010242308A1/en not_active Abandoned
- 2010-04-28 WO PCT/JP2010/057923 patent/WO2010126168A2/en active Application Filing
- 2010-04-28 MX MX2011011011A patent/MX2011011011A/es not_active Application Discontinuation
- 2010-04-28 MA MA34358A patent/MA33280B1/fr unknown
- 2010-04-28 CA CA2760073A patent/CA2760073A1/en not_active Abandoned
- 2010-04-28 CN CN2010800289702A patent/CN102481248B/zh active Active
- 2010-04-28 EA EA201171329A patent/EA201171329A1/ru unknown
- 2010-04-28 NZ NZ596395A patent/NZ596395A/xx not_active IP Right Cessation
-
2011
- 2011-10-26 DO DO2011000329A patent/DOP2011000329A/es unknown
- 2011-10-26 CL CL2011002662A patent/CL2011002662A1/es unknown
- 2011-10-26 IL IL215962A patent/IL215962A0/en unknown
- 2011-11-08 CR CR20110581A patent/CR20110581A/es unknown
- 2011-11-15 ZA ZA2011/08375A patent/ZA201108375B/en unknown
- 2011-11-30 EC EC2011011494A patent/ECSP11011494A/es unknown
- 2011-11-30 CO CO11164599A patent/CO6470841A2/es not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012525323A5 (xx) | ||
HRP20120667T2 (hr) | Derivat benzimidazola i njegova uporaba kao antagonista aii receptora | |
NZ596395A (en) | Stable solid benzimidazole derivative preparation having optimized dissolution property | |
HRP20160987T1 (hr) | Farmaceutski oblik doziranja koji sadrži nifedipin ili nisoldipin i antagonist angiotenzina-ii i/ili diuretik | |
CA2613417A1 (en) | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker | |
CA2514921A1 (en) | Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension | |
TWI246921B (en) | Stabilized pharmaceutical composition with calcium blocker | |
JP2010507602A5 (xx) | ||
JP2014531461A5 (xx) | ||
PE20040325A1 (es) | Nuevas composiciones farmaceuticas basadas en anticolinergicos e inhibidores de la p38 quinasa | |
RU2004137105A (ru) | Комбинация органических соединений | |
JP2017523972A5 (xx) | ||
JP2010265321A5 (xx) | ||
JP2012533546A5 (xx) | ||
JP2020506180A5 (xx) | ||
NO20085121L (no) | Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme | |
JP2010513322A5 (xx) | ||
RU2019126749A (ru) | Композиции для лечения гипертензии | |
US20090221656A1 (en) | Drug Combinations | |
WO2006107062A3 (en) | Benzimidazole derivative and use as angiotensin ii antagonist | |
PE20110844A1 (es) | Composicion farmaceutica solida | |
JP2014532754A5 (xx) | ||
JP2013501729A5 (xx) | ||
JP2012515788A5 (xx) | ||
US10111858B2 (en) | Pharmaceutical for prophylaxis or treatment of hypertension |